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Abstract
Visceral leishmaniasis is a major neglected tropical disease, with an estimated 500,000 new cases and more than 50,000
deaths attributable to this disease every year. Drug therapy is available but costly and resistance against several drug classes
has evolved. Despite all efforts, no commercial, let alone affordable, vaccine is available to date. Thus, the development of
cost effective, needle-independent vaccines is a high priority. Here, we have continued efforts to develop live vaccine
carriers based on recombinant Salmonella. We used an in silico approach to select novel Leishmania parasite antigens from
proteomic data sets, with selection criteria based on protein abundance, conservation across Leishmania species and low
homology to host species. Five chosen antigens were differentially expressed on the surface or in the cytosol of Salmonella
typhimurium SL3261. A two-step procedure was developed to select optimal Salmonella vaccine strains for each antigen,
based on bacterial fitness and antigen expression levels. We show that vaccine strains of Salmonella expressing the novel
Leishmania antigens LinJ08.1190 and LinJ23.0410 significantly reduced visceralisation of L. major and enhanced systemic
resistance against L. donovani in susceptible BALB/c mice. The results show that Salmonella are valid vaccine carriers for
inducing resistance against visceral leishmaniasis but that their use may not be suitable for all antigens.
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Introduction
The leishmaniases are regarded as neglected tropical diseases.
The causative protozoan parasites are transmitted through the bite
of sandfly vectors. Currently an estimated 12 million people are
infected, while 350 million people in 88 countries worldwide are at
risk to develop one of the diseases associated with Leishmania
parasites (http://www.who.int/leishmaniasis/burden/en/; [1]).
The most severe form is visceral leishmaniasis (VL; also known
as kala azar in India) a disease that is fatal if untreated. An
estimated 500 000 new cases and 50 000 deaths are reported
every year, with 90% occurring in Bangladesh, Nepal, India,
Sudan, Ethiopia and Brazil ([2]). VL caused by L. infantum/chagasi
is zoonotic with dogs being the main reservoir; however, in areas
endemic for L. donovani (e.g. India and Sudan) the disease is
anthroponotic.
In many cases infection remains asymptomatic, most likely
indicating immune control. However, patients with symptomatic
VL experience fever, fatigue, weight loss and weakness often
accompanied by hepato-splenomegaly and anaemia and, if
untreated, may die from bacterial co-infections, internal bleeding
and anaemia (reviewed by (2]). Chemotherapy is available, but
due to high toxicity, adverse side effects and emerging parasite
resistance, treatment options are limited [3–6]. Long treatment
regimens and associated costs are additional critical factors
preventing patient access and compliance. For example paromo-
mycin, a newly registered drug, is given by intra-muscular
injections over a period of 21 days. Though the cheapest drug
available, treatment still costs between 5 and 10 US$ per course,
making this drug too expensive in relation to household income
[5]. This economic burden of treatment is likely to remain for the
foreseeable future. Thus, developing a vaccine for VL (and indeed
for other forms of leishmaniasis) is high on the agenda of the
World Health Assembly (resolution EB118.R3, Geneva 05/07).
Vaccination is considered possible because of the efficacy of the
century-old practice of leishmanization against old world cutane-
ous leishmaniasis (CL), a treatment that affords life long protection
as proven during its large scale use to protect military personnel in
Israel, Iran and the former Soviet Union [7–9]. However, in some
individuals, development of non-healing lesions, exacerbation of
chronic disease and immunosuppression as a result of this
procedure has been observed [10]. The unsatisfactory safety
profile, its questionable efficacy against infection with heterologous
species and logistic hurdles render leishmanization problematic.
Vaccines that relied on autoclaved or merthiolate-killed whole
promastigotes formulated with or without Bacillus Calmette-
Guerin as adjuvants were developed to remedy some of the
shortcomings of leishmanization but a recent meta-analysis of
www.plosntds.org 1 December 2011 | Volume 5 | Issue 12 | e1406clinical studies evaluating these vaccines did not support their
efficacy [11].
Clinical testing of vaccines based on recombinant Leishmania
antigens or fractionated parasite material is much less advanced,
although numerous antigenic proteins have been shown to have
vaccine potential in pre-clinical models (see reviews by [12–14]).
These antigens were usually discovered by classical approaches,
i.e. by screening with immune or hyperimmune sera from patients
or infected animals. Antibody reactivity may not be an ideal
criterion since protection is cell mediated and is thought to depend
on both CD4
+ and CD8
+ T lymphocytes [15–18]. More recently,
however, parasite genome information has become available and
vaccine-antigen discovery exploiting this information has been
promoted [19]. Recombinant DNA technology enables the
formulation of subunit vaccines consisting of one or few specified
antigens as DNA- and vectored vaccines, the latter exploiting
viruses or bacteria as vaccine vehicles (summarised by [12,20,21]).
Indeed, expressed sequence-tag based vaccine antigen discovery
has been explored [22]. However, of 100 ORFs tested only 14
showed detectable protective effects when tested in a high dose
infection model of murine CL. This was probably not surprising
given that gene expression is regulated mainly post transcription-
ally in Leishmania and suggests a need to improve sequence
selection criteria.
Here, we adapted a reverse vaccinology [23] approach to define
novel candidate vaccines, starting from proteomic data sets that
were generated recently [24] and ignoring whether or not proteins
would be recognized by sera from infected hosts. Moreover, we
optimized recombinant attenuated Salmonella as a vaccine carrier
platform since they had been explored before as vectors for anti-
Leishmania vaccines [25–27] and have already been developed for
vaccination purposes in humans [28–30].
Materials and Methods
Mice
Female BALB/c mice were purchased from Harlan UK,
Charles River UK or bred and maintained under specific
pathogen-free conditions in individually ventilated cages in the
animal facilities of the School of Biological Sciences at the
University of Edinburgh and the University of York. Animals were
used at 6–9 weeks of age and were age matched within each
experiment. All animal experiments adhered to the UK Animals
(Scientific Procedures) Act 1986 and were conducted under
Project Licenses granted by the UK Home Office and with local
ethical approval (License # PPL 60/03581 to TA and PPL 60/
03708 to PK).
Construction of expression plasmids
To inducibly express antigens on the surface of Salmonella, the E.
coli adhesin involved in diffuse adherence (AIDA) autotransporter
system was adapted and a variant of plasmid pKRI143 [31] was
constructed, pAIDA0, as previously described [32]. Briefly, the
sequence encoding cholera toxin B subunit signal peptide was
followed by SpeI/BglII sites for in frame directional cloning of ORF
of interest fused with downstream sequences coding for a
hemagglutinin epitope (HA)-tag and the transporter domain of
AIDA, all under the control of the in vivo inducible Mg
2+
responsive PpagC promoter [33].
Vaccine antigen ORFs encoding L. donovani KMP-11
(LinJ35_V3.2260), ORF LinJ08.1190 (LinJ08_V3.1190), ORF
LinJ09.1180 (LinJ09_V3.1180), ORF LinJ23.0410 (LinJ23_
V3.0420), ORF LinJ25.1680 (LinJ25_V3.1670) and ORF LinJ
35.0240 (LinJ35_V3.0140) were amplified from L. donovani
(MHOM/INI/03BHU-55) genomic DNA using primers shown
in table 1. ORF nomenclature and accession numbers are
indicated in Table 2. Amplifications were carried out with the
PlatinumH Pfx DNA Polymerase kit (Invitrogen). PCR products
were digested with SpeI and BglII and cloned into the equally
digested pAIDA0 for transformation into SL3261 and E. coli
JK321(UT5600 zih::Tn10 dsbA::kan) [34], respectively.
To differentially regulate protein expression levels, point mutations
were introduced into the Shine-Dalgarno ribosomal binding
sequence (RBS; underlined) using site directed mutagenesis. Forward
primer for RBS3 (59-GATCAATCTAGATTTAAGAAGCAGA-
TATACATATGATTAAATTAAAATTTGGTG-39), RBS4 (59-
GATCAATCTAGATTTAAGAAGGGAATATACATATGATT-
AAATTAAAATTTGGTG-39)a n dR B S 5( 5 9-GATCAATCT-
AGATTTAAGAAAGAAATATACATATGATTAAATTAAA-
ATTTGGTG-39) were designed to amplify the cholera toxin signal
peptide, HA-tag and antigen while simultaneously introducing the
mutated Shine-Dalgarno sequence upstream of the signal peptide.
The resulting PCR product was SpeI/BglII digested and re-ligated
into pAIDA-Antigen. All resulting surface expression plasmids were
subsequently named psVAC[# of RBS mutation]-antigen.
For expression of antigens in the salmonella cytosol L. donovani
ORFs were amplified using primers described in Table 1.
Resulting PCR products flanked by 59 NdeI and 39 BamHI sites
were digested and first cloned downstream of a PpagC promoter
into a pBR322-derived plasmid series already containing mutated
Shine-Dalgarno sequences (RBS1 – AGGAA, RBS2 – GGGAA
and RBS3 – AGCAG) described in [35] for transformation into
SL3261. The resulting plasmids were subsequently named
pcVAC[# of RBS mutation]-antigen. Preparation of live vaccine
stocks, immunizations and determination of bacterial fitness by in
vivo colonisation have been performed exactly as described before
[32].
Purification of recombinant proteins
For generating recombinant proteins, Leishmania antigen
ORFs were cloned into pET28a(+) (Novagen). All antigens
were amplified using the NdeIa n dBamHI site containing
Author Summary
The leishmaniases are tropical diseases that affect the
poorest of the poor. They are caused by Leishmania
species, protozoan parasites transmitted by blood sucking
insects and the visceral form of the disease is fatal.
Vaccines that would tremendously boost disease control
strategies need to be designed cost-efficiently and for the
existing infrastructure. Salmonella-based live vaccines
could fulfil these requirements as they can be cheaply
produced on an industrial scale and the lyophilized
product can be stored at room temperature and upon
rehydration is ready for oral, needle-free application.
Salmonella, like Leishmania, are intracellular pathogens
that primarily target host macrophages. The bacteria
induce a viscerotropic immune response. Herein lies a
potentially significant advantage of using attenuated
Salmonella as delivery vehicles for parasite antigens for
vaccination against visceral leishmaniasis. We used in vivo
inducible promoters and optimized expression systems to
construct attenuated Salmonella carriers that deliver novel
vaccine antigens and show a host protective effect in small
rodent models of visceral leishmaniasis. These proof-of-
concept studies should serve to further promote explora-
tion of live Salmonella as a cost effective and widely
applicable carrier for vaccination against leishmaniases.
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as described previously [32]. KMP-11, the only soluble protein
was directly purified on a Nickel column (1 ml, HisTrap FF,
GE Healthcare). All other antigens formed inclusion bodies
w h i c hn e e d e dt ob ei s o l a t e da n dd i s s o l v e dp r i o rp u r i f i c a t i o n
under denaturing conditions with an on-column refolding step
[32].
Recombinant protein containing fractions eluted from col-
umns (see Fig. S1) were pooled and protein concentrations
determined using amidoblack [36]). Proteins LinJ08.1190,
LinJ09.1180, LinJ23.0410 and LinJ25.1680 became insoluble
when imidazole was removed; hence 50 ml/well of a 50 mg/ml
protein eluate was used to coat 96-well plates (MaxiSorb, Nunc)
for ELISA. Plates were sealed and stored at 4uC until needed.
For T cell re-stimulation assays imidazole was removed by
dialysis against TBS/150 mM NaCl and subsequently concen-
trated by ultrafiltration using CentriconsH (Millipore) of appro-
priate pore size.
Table 1. List of primers used for amplifying antigens from parasite DNA.
Antigen Expression system
Sequence 59R39
(enzyme restriction sites are shown in bold)
KMP-11 Surface
psVAC
F GATCAAACTAGTGCCACCACGTACGAGGAG
R GATCAAAGATCTCTTGGATGGGTACTGCGCAGCC
Cytosol
pcVAC
F GATCAACATATGGCCACCACGTACGAGGAG
R GATCAAGGATCCGTCGATTACTTGGATGGGTACTGCGCAGCC
LinJ08.1190 Surface
psVAC
F GATCAAACTAGTTCTCAGCAGCTCGCCTTCC
R GATCAAAGATCTCGGGTGGCTGTCGTCGGCGGC
Cytosol
pcVAC
F GATCAACATATGTCTCAGCAGCTCGCCTTCC
R GATCAAGGATCCGTCGATTACGGGTGGCTGTCGTCG
LinJ09.1180 Surface
psVAC
F GATCAAACTAGTTCCCCTCTGCAGCAGGCACGCTGG
R GATCAAAGATCTCACTTTTCGGGAAAAACCAGTG
Cytosol
pcVAC
F GATCAACATATGTCCCCTCTGCAGCAGGCACGCTGG
R GATCAAGGATCCGTCGACTACACTTTTCGGGAAAAACC
LinJ23.0410 Surface
psVAC
F GATCAAACTAGTCTTCACTTCCCCATTTCGCCC
R GATCAAAGATCTCCAGCCGCGGTGATAGAGG
Cytosol
pcVAC
F GATCAACATATGCTTCACTTCCCCATTTCGCCC
R GATCAAGGATCCGTCGATTACCAGCCGCGGTGATAGAGG
LinJ25.1680 Surface
psVAC
F GATCAAACTAGTTCGTCCGAGGTTGCGATTCAGC
R GATCAAAGATCTCTGCTGCTGCTTCTCCGG
Cytosol
pcVAC
F GATCAACATATGTCGTCCGAGGTTGCGATTCAGC
R GATCAAGGATCCGTCGACTACTGCTGCTGCTTCTCC
LinJ35.0240 Surface
psVAC
F GATCAAACTAGTCTGCGCCACTCGCTGCTTCG
R GATCAAAGATCTCCACCAGGCTGCCTTGCGGATGC
Cytosol
pcVAC
F GATCAACATATGCTGCGCCACTCGCTGCTTCG
R GATCAAGGATCCGTCGACTACCACCAGGCTGCCTTGC
doi:10.1371/journal.pntd.0001406.t001
Table 2. Nomenclature and accession numbers of genes
encoding the novel antigens investigated.
In manuscript
In TriTrypDB
1)
(version 22.06.2011)
NCBI Reference sequence
Acc. Number
LinJ.08.1190 LinJ.08.1190 XM_001463411.1
LinJ.09.1180 LinJ.09.1180 XM_001463538.1
LinJ.23.0410 LinJ.23.0420 XM_001465681.1
LinJ.25.1680 LinJ.25.1680 XM_001466162.1
LinJ.35.0240 LinJ.35.0140 XM_001468797.1
1)Aslett et al. TriTrypDB: a functional genomic resource for the
Trypanosomatidae Nucleic Acids Research 2010 38(Database issue):D457–
D462; doi:10.1093/nar/gkp851.
doi:10.1371/journal.pntd.0001406.t002
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ELISA for antigen-specific antibodies of different isotypes (IgG1
and IgG2a) from mouse serum has been performed as previously
described [32]. In brief, serial dilutions of individual sera were
analysed. To estimate relative antibody concentrations, titers were
determined corresponding to the value of the serum dilution giving
a half maximal ELISA signal.
L. major infection and determination of parasite burden
in limiting dilution assays
L. major promastigotes were grown in semi-defined medium until
late stationary phase was reached. Two million parasites were
injected into the left hind footpad and lesion size was measured as
the difference in thickness between infected and uninfected
footpad using a calliper. For determination of parasite numbers
in organs mice were sacrificed by cerebral dislocation and organs
(spleen, draining lymph node, footpad) were removed and
homogenized. The single cell suspensions were adjusted to equal
volumes and subjected to serial dilutions in 96-well tissue culture
plates filled with SDM medium [24] supplemented with 20 mg/ml
hygromycin and 50 mg/ml kanamycin, which was carried out in
quadruplets. After 14 days at 27uC, parasite growth was scored
microscopically and parasite load in the infected organs was
calculated using the dilution where at least 2 of 4 wells (.37.5%)
were positive [37]. This dilution was multiplied by the total
volume (in multiples of 0.1 ml) to derive the total number of
parasites per organ.
Determination of hepato-splenomegaly and L. donovani
burden in impression smears
Mice were killed by cervical dislocation and livers and spleens
were removed and weighed. The body-mass index (BMI) was
calculated as the organ weight in percentage of body weight. To
determine parasitic burden in spleen and liver, impression smears
were prepared on microscopic glass slides, fixed in methanol and
stained with Giemsa. The number of parasites per 1000 host cell
nuclei was counted using a light-field microscope and an
immersion oil lens. Leishman-Donovan units (LDU) were
calculated by multiplication of the number of parasites/1000
nuclei with the organ weight [38].
Histopathological analysis of hepatic response to L.
donovani
Liver sections were processed for immunohistochemistry as
described in detail elsewhere [39]. Briefly, confocal microscopy
was performed on acetone fixed 8 mm frozen sections stained with
Alexa 488-conjugated F4/80 (eBioscience, United Kingdom and
purified rabbit anti-mouse inducible nitric oxide synthase (iNOS)
(Abcam, United Kingdom) detected with donkey anti-rabbit Alexa
647. Sections were counterstained with 49,69-diamidino-2-pheny-
lindole (DAPI), and mounted in Pro-Long Gold antifade
(Invitrogen) for examination on a LSM META 510 confocal
microscope (Zeiss). Quantification of NOS2 staining was per-
formed on randomly selected fields for each mouse, using Adobe
Photoshop CS3 to determine the area of iNOS reactivity (as
number of positively stained pixels) relative to total granuloma
area (as pixels stained with F4/80). Granuloma maturation was
assessed from hematoxylin-eosin (H&E)-stained tissue sections as
described elsewhere [39].
Statistical analysis
Statistical analysis was performed using GraphPad Prism
Program (Version 4.0, GraphPad Software, San Diego, Califor-
nia). Depending on data passing normality tests, ANOVA was
performed with appropriate post-tests for pairwise comparisons or
Mann-Whitney tests were computed. P values less than 0.05 were
considered significant.
Results
In silico selection of novel antigen candidates from
Leishmania
For the selection of novel antigen candidates, we conducted a
bioinformatic analysis of a proteomic dataset that compared the
proteomes of pro- and amastigote stages of L. mexicana [24]. This
data set was chosen because to date this is the only dataset
containing information on truly intracellular parasites and because
a comparison with data from a proteomic analysis of L. donovani
axenic amastigotes suggested a very high degree of overlap with
respect to abundant proteins [24]. From a total of 509 proteins
that reflect the set of highly abundant proteins, we selected five
novel antigen candidates based on abundance, conservation
throughout the genus and lack of homologies to host proteins
(Figure 1). These criteria and, in addition, predicted subcellular
localization were found before to be valuable to identify antigens
for induction of protective T cell responses from complex
organisms, operationally defined here as expressing &10
3 different
protein antigens, e.g. to select antigens for vaccines against
Helicobacter pylori [40]. A further, Leishmania-relevant criterion was
the expression of the potential antigen in appropriate life cycle
stages. Preference was given to proteins expressed in the disease-
causing intracellular amastigote stage, but, since early stages of
infection after transmission of promastigotes were also considered
relevant, antigen expression in both life cycle stages was not an
exclusion criterion. Four selected antigens were present in the
proteomic datasets of both stages while the LinJ23.0410
corresponding protein was present only in the amastigote dataset.
Homologues of the encoding genes were found in all cases in L.
major, L. infantum, L. donovani and L. braziliensis genomes with a very
high degree of conservation (ranging from 78.9% to 95.8%
identity of amino acid sequence, increasing to 87.6% to 99% when
including conserved substitutions). Sequence homologies to
proteins of mouse and human (human as final target and mouse
as a model host) were excluded by BLAST searches. This
approach was biased and preferentially excluded similar sequence-
dependent epitopes. It was used here because it was assumed to
enhance the likelihood of antigens to be recognized by T cells as
‘‘foreign’’ and to reduce the risk of potential autoimmune
sequelae.
Novelty and expressability in our salmonella expression systems
were additional final selection criterion but we also included the
well characterized antigen KMP-11 as a reference vaccine antigen.
This antigen has been shown to be protective against L. donovani,
when administered as a DNA vaccine [41,42].
Generation and optimization of S. typhimurium vaccine
carrier strains
Subcellular localization and protein amount are not only useful
criteria to select T cell vaccine antigens, they are also crucial
parameters to consider in the construction of recombinant live
vaccine carriers - such as bacteria - to induce antigen-specific cell
mediated immunity [43,44]. Thus, two expression systems were
adapted that directed antigens either to the cytosol or the surface
of Salmonella and allow induced expression via the in vivo inducible
promoter PpagC. We choose to control antigen production at the
translational level and introduced a set of point mutations into a
canonical ribosomal binding site (RBS) creating a set of four
Live Anti-Leishmania Salmonella Vaccine
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These mutations resulted in staggered protein expression levels
when Salmonella strains carrying the respective plasmids were
grown under conditions that activate the PpagC promoter (Figure
S2). Heterologous protein expression can greatly reduce fitness of
the carrier bacteria in vivo, thereby critically affecting the amount
of total antigen delivered to the immune system and thus vaccine
immunogenicity. This relationship is schematically shown in
Figure 2A (left panel) and, as an example, is shown for vaccine
strains engineered for cytosolic expression of LinJ23.0410
(Figure 2A, right panel). Colonisation of the Peyer’s patches seven
days after oral administration of 10
9 CFU was determined as a
measure of bacterial fitness. Expression of LinJ23.0410 was clearly
negatively correlated with the number of CFU found in Peyer’s
patches, i.e. vaccine strain fitness. Use of a canonical, non-mutated
RBS (RBS0) resulted in high amounts of protein but greatly
reduced bacterial fitness. Introduction of point mutations (RBS1,
2, 3) lowered expression levels from intermediate (RBS1) to very
low (RBS2 and 3) which brought fitness back to the level of the
empty carrier strain (Figure 2A right panel). A reduction of
bacterial fitness far below 10
4 CFU in this assay, based on past
experience (JS and TA unpublished), rendered vaccine strains
non-immunogenic with respect to the recombinantly expressed
antigen. Thus, out of 48 bacterial strains constructed and
evaluated as shown for the example above, 10 strains were
selected for further testing. Their respective fitness and antigen
expression characteristics were as shown in Figure 2B.
Interestingly, antigens LinJ08.1190, LinJ09.1180, LinJ25.1680
and LinJ35.0240 could not be expressed in the cytosol (data not
shown) but vaccine strains could be obtained, with the exception of
LinJ35.0240, when the antigens were targeted to the bacterial
surface. In consequence, only two vaccine strains expressing the
antigens KMP-11 and LinJ23.0410 cytosolically could be included
in the panel (Figure 2B, right panel). In addition, eight surface
expression strains were selected (Figure. 2B, left panel). Surface
expression of antigen LinJ35.0240 could not be detected via
western blot despite a clear influence on bacterial fitness (Figure 2B
left panel). Based on the latter, it was therefore decided to include
psVAC5-35.0240 as an example for the respective antigen.
Protection of mice against L. major
All selected strains were next tested in vivo for their ability to
protect BALB/c mice against visceralising L. major infection. These
mice are highly susceptible to L. major infection, and have been
suggested to provide a good mouse model for VL. Mice were
vaccinated with a single dose of Salmonella vaccine strains, the
carrier control SL3261 or treated with PBS. Mice were
subsequently challenged with 2610
6 late-stationary phase L. major
promastigotes into the left hind footpad. Lesion size was
monitored over a course of several weeks after which mice were
randomized and selected for analysis of parasitic burden in
footpad, lymph node and spleen.
A pilot study involving all 10 selected vaccine strains showed
that vaccination with Salmonella carrying antigens LinJ08.1190 and
LinJ23.0410 reduced lesion size and parasitic burden compared to
the controls (see Figure S3). Interestingly, vaccination with antigen
LinJ25.1680 expressing Salmonella exacerbated disease while the
other vaccines including the KMP-11-expressing strains had no
effect on disease progression compared to controls (Figure S3).
Thus, the presumably protective vaccine strains psVAC5-
08.1190, pcVAC1-23.0410 and psVAC0-23.0410 as well as a
mixture of these (from hereon named ‘vaccine allstars’), were
further evaluated (Figure 3). Vaccination, especially with psVAC5-
08.1190 and vaccine allstars, significantly delayed the onset and
progression of footpad swelling in mice challenged nine weeks later
(Figure 3A). Five weeks after infection, five animals per groups
were selected randomly and parasitic burden in spleen, popliteal
lymph node and footpad was determined. Parasite numbers in
footpads and lymph nodes were not significantly different in the
vaccine groups (Figure 3B, C) although a trend towards lower
burdens was notable in mice vaccinated with psVAC0-23.0410,
psVAC5-08.1190 and vaccine allstars (Figure 3B, C). The
discrepancy between lesion size and parasite burden was surprising
but is not without precedence. The inverse situation has been
described in murine L. major infection when analysing TNR-p55
receptor deficient mice [45] or when mapping susceptibility loci
[46,47]. However, mechanisms are currently not fully understood.
The parasitic burden in the spleen was assessed as a surrogate
marker of protection against visceral leishmaniasis. Immunisation
with the psVAC5-08.1190 and allstars vaccines significantly
reduced parasite numbers in the spleen compared to challenged
only mice and a similar trend was noted for the surface expressing
psVAC0-23.0140 vaccine (Figure 3D). Of note, five animals
amongst those vaccinated with psVAC5-08.1190 and vaccine
Figure 1. Schematic overview of criteria applied in antigen
selection process. I: Abundance: A proteomic data set (c.f. Table S1 in
ref. [24] consisting of 509 different proteins representing the most
abundant proteins of L. mexicana was used as a starting set describing
potential vaccine antigens. II: No sequence homology to target
vaccination populations and conservation within Leishmania spp.: these
criteria can be applied more or less stringently, we applied stringent
thresholds for selecting against homologous proteins by focusing only
on hypothetical conserved proteins (c.f. Table S1 in ref. [24] that at time
of selection included LinJ09.1180) whereby the number of candidates
was reduced to 185 at this step of selection. III: Life-cycle stage
occurrence: proteomic evidence for expression of candidates in
amastigotes or throughout the life cycle was required reducing the
candidate list to 39 proteins. Preference was given in step VI to a set of
six based on likelihood to be expressible as AIDA autotransporter fusion
proteins in salmonella carriers and by re-iterating the selection based
on conservation within the genus resulting in candidates with sequence
identity .78%.
doi:10.1371/journal.pntd.0001406.g001
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Hence, a single oral dose of Salmonella vectored vaccines that
delivered both LinJ08.1190 with LinJ23.0410 significantly reduced
visceral L. major parasite burdens in these highly susceptible
BALB/c mice.
Protection of mice against L. donovani
Since conservation of the antigens among Leishmania species was
a key selection criterion, we hypothesised that antigens which were
protective against L. major would also protect against the causative
agent of human VL, L. donovani. To test this hypothesis, we
immunised BALB/c mice with strains psVAC5-08.1190 and
vaccine allstars. Leishmania surface antigen KMP-11 had been
shown to be protective against L. donovani in mice [42]. Therefore
and despite its poor performance in previous experiments,
Salmonella strain pcVAC1-KMP, expressing KMP-11 in the
cytosol, was included together with the carrier strain SL3261
and sham-immunisation in this study. Mice vaccinated with a
single oral dose were challenged intravenously with 3610
7 L.
donovani amastigotes six weeks later. A characteristic for L. donovani
infection in BALB/c mice is hepato-splenomegaly and the organ-
specific control of the infection. Half of the mice were sacrificed on
day 28 p.i., when liver parasite burden has usually reached its peak
before the onset of self cure and when splenic parasite burden has
begun to increase. The remaining animals were analysed at day
68 p.i. to assess long term control, particularly in the spleen.
An increased ratio of liver/spleen weight to body weight is an
indirect measure of L. donovani infection induced inflammation and
disease severity. Thus, body and organ weights were determined at
necropsy (Table S1). The ratio for both liver (Figure 4A) and
spleen (Figure 4B) increased between day 28 and day 68 in non-
vaccinated animals and mice treated with either the carrier
salmonella alone or the pcVAC1-KMP vaccine. In contrast, in
animals vaccinated with psVAC5-08.1190 or the allstars vaccine,
Figure 2. Two step strategy for the selection of vaccine strains for in vivo testing. Candidate antigen expression and ability to colonize
Peyer’s patches after intragastric inoculation was determined experimentally to select optimal strains. Expression of the HA-tagged antigens was
assessed by SDS-PAGE in lysates of vaccine strains grown under low Mg
2+ conditions to mimic the in vivo intraphagosomal environment that
activates the PpagC promoter. Vaccine antigen expression was visualized by coomassie stain (cytosol expressing strains) or by Western blot analysis
using an anti-HA tag antibody (surface expressing strains). (A, left panel) A schematic plot is shown to illustrate how the degree of foreign antigen
expression reduces bacterial fitness and how both factors influence the immunogenicity of a carrier strain. (A, right panel) Real data example of
fitness as a function of antigen expression using SL3261 expressing increasing amounts of LinJ23.0410 in the cytosol. (B) Characteristics of bacterial
fitness and recombinant protein produced by final selected strains with surface (left panel) or cytosolic (right panel) expression.
doi:10.1371/journal.pntd.0001406.g002
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B). Mice immunized with psVAC5-08.1190 or the allstars vaccine
had a mean liver parasite burden of 84.20639.30 and
69.75620.74 LDU, respectively at day 68 p.i. significantly
reduced in comparison to the non-immunized group
(361.0666.79 LDU), the SL3261 carrier (189.0663.79 LDU) or
the pcVAC1-KMP treated animals (232.2630.02 LDU;
Figure 4C). Of note, the decrease noted after SL3261 treatment
in comparison with the naı ¨ve controls was also significant
(Figure 4C). The effects of the vaccines on splenic parasite
burdens followed the same pattern (Figure 4D). Mice immunized
with psVAC5-08.1190 or the allstars vaccine controlled parasite
replication while numbers increased significantly between day 28
and 68 in all other study groups (Figure 4D). Immunisation with
pcVAC1-KMP also did not protect mice from L. donovani infection
and parasite burden increased over time (69.80618.67 to
182.8661.53), which was similar for SL3261 treated mice
(Figure 4D).
In summary, a single oral dose of salmonella vectored vaccines
delivering LinJ08.1190 and/or LinJ23.0410 significantly reduced
hepato-splenomegaly and visceral infection in mice infected with
L. donovani, the causative agent of human VL.
Immune responses
To assess immune responses during vaccination and infection,
we measured antigen-specific antibody isotype titres as a surrogate
of the underlying CD4
+ T cell response, given the known
correlation between IL-4 and IgG1 responses and between IFNc
and IgG2a [48]. Serum was assessed in vaccinated mice four
weeks after immunisation and on day 28 and 68 post infection
Figure 3. Vaccination significantly reduces L. major infection in BALB/c mice. Ten mice per group were immunised intra-gastrically with
10
10 CFU of salmonella vaccine strains and infected 9 weeks later with 3610
6 stationary-phase L. major promastigotes into the left hind footpads.
Footpad swelling (A) was monitored with a calliper using the uninfected right foot for reference. Values represent the mean 6 standard error of the
mean swelling per group and time point. Asterisks denote statistically significant differences (* P#0.05, ** P#0.01, *** P#0.001; two tailed Mann-
Whitney U test). Five weeks after infection 5 mice of each group were randomly selected and killed to determine parasite burden in footpads (B),
draining lymph nodes (C) and spleens (D) by limiting dilution culture assay. The detection limit of the respective assays based on starting dilution was
65 parasites for spleen and 6500 for lymph node or footpad. The values of the burden per organ of all individual mice and median burden per group
are shown. The asterisks denote statistically significant differences (* P#0.05, ** P#0.01; two-tailed Mann-Whitney U test). Error bars show standard
error of the mean (SEM).
doi:10.1371/journal.pntd.0001406.g003
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after vaccination but before infection, vaccine antigen-specific
antibody titers were below the limit of detection (Figure 5A–F). In
agreement with the fact that KMP-11-specific antibodies are
produced during human VL [49], infected non-vaccinated mice or
SL3261 carrier immunized mice generated anti-KMP-11 anti-
bodies (Figure 5A, B). This anti-KMP-11 response was very similar
in the pcVAC1-KMP vaccinated group (Figure 5C). In contrast,
vaccines expressing LinJ08.1190 and/or LinJ23.0410 primed
animals for the production of specific antibodies that became
detectable after the boosting infection on day 28 and 68 post
infection (Figure 5D–F) but no antibodies against the respective
recombinant proteins were detectable by ELISA (detection limit of
assay was at titers #20) during infection in naı ¨ve, SL3261 or
pcVAC1-KMP treated animals (not shown). This indicated that
LinJ08.1190 and/or LinJ23.0410 were not naturally immunogenic
during infection of BALB/c mice.
Next, the ratios of vaccine antigen-specific IgG1 and IgG2a
were calculated for each mouse and time point (Figure 6) to seek
evidence for a bias in type 1 vs. type 2 immune response. Over the
course of infection significant and different skewing was noted
between the treatment groups. Anti-KMP-11 IgG1 to IgG2a ratios
were above 1 in pcVAC1-KMP vaccinated mice which was
therefore not different from the response to KMP in infected only
or SL3261 vaccinated mice. In comparison, anti-vaccine antigen
specific IgG1 to IgG2a ratios, however, were significantly different
in sera from psVAC5-08.1190 or allstars vaccinated mice with
values around 1 or below (Figure 6; p,0.05).
Figure 4. Vaccination significantly reduces L. donovani infection in BALB/c mice. Ten mice per group were immunised intra-gastrically with
10
10 CFU salmonella vaccine strains and 6 weeks later infected with 3610
6 lesion-derived L. donovani amastigotes. Five mice per group were
sacrificed at day 28 and five at 68 post infection. Animals were weighed and spleen and liver organ weights were determined to compute organ to
body weight ratios for liver (A) and spleen (B). Giemsa stained impression smears of liver (C) and spleen (D) were assessed under the microscope and
parasites per 1000 nuclei expressed as Leishman-Donovan Unit (LDU). * P#0.05, ** P#0.01, *** P,0.001; one-way ANOVA and Tukey post-test. Error
bars show standard error of the mean (SEM).
doi:10.1371/journal.pntd.0001406.g004
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direct manner, we examined the level of granulomatous
inflammation in infected mice that were either unvaccinated or
had been vaccinated with control SL3261 Salmonella or with
allstars (Figure 7). At day 28 p.i, there was a small but significant
increase in the number of granulomas observed in the liver of
allstars vaccinated mice (Figure 7A). We next measured the
maturation stage of each granuloma, using established scoring
criteria [39]. Granuloma maturation was similar between all
groups of mice at day 28 p.i. (with a small but not significant trend
towards enhanced maturation in allstars vaccinated mice). By day
68 p.i., however, mice vaccinated with either SL3261 or allstars
showed enhanced granuloma maturation compared to non
vaccinated mice. Although the results of this analysis are in
keeping with the enhanced ability of these vaccinated mice to
reduce parasite burden, it was not a sufficiently sensitive technique
to discriminate between the resistance induced by SL3261 and
allstars (c.f. Figure 4D). Finally, we measured the area within each
granuloma that stained positive for iNOS, as one measure of
functional capacity at these inflammatory foci. There were no
significant differences in the iNOS response between vaccinated
and non-vaccinated mice at either time point by this criterion
(Figure 7D). Hence, the main tissue correlate of protection
induced by allstars vaccination was an increase in the rapidity of
granuloma formation, suggesting that vaccination may have
heightened the frequency of CD4
+ and/or CD8
+ T cells able to
facilitate this focal inflammatory response.
Discussion
We had previously reported on the proteome of the intracellular
amastigote stage of L. mexicana [24] which showed extensive
overlap with proteins identified in L. donovani axenic amastigotes
[50]. Because of this overlap, the former proteomic dataset was
exploited here to adapt a reverse vaccinology approach to develop
a vaccine against VL. We applied the criteria of protein
abundance, within parasite genus conservation, and absence of
homologous proteins in host organisms to select novel candidate
vaccine antigens aimed to induce cellular immunity. These criteria
may not be optimal though to select targets for inducing antibody-
dependent immunity. Four of five selected candidates could be
Figure 5. Analysis of antigen-specific humoral response in
vaccinated L. donovani infected mice. IgG1 and IgG2a antibody
isotypes specific for the respective vaccination antigen were determined
in sera from each mouse individually by ELISA using plates coated with
purified antigens KMP-11, LinJ08.1190 and LinJ23.0410. Titers of
antibodies recognizing specific antigens of sera prepared at the indicted
time points are shown from naı ¨ve (A), SL3261 carrier control (B) and
pcVAC1-KMP vaccine strain (C) immunized animals or psVAC5-08.1190
vaccine (D) or vaccine allstars (E, F) treated mice. Values represent mean
titers calculated from individually tested sera. The test had a sensitivity to
detect antibodies with titers of ,20. Error bars show standard error of
the mean (SEM). n.d. not detected. Statistical significance: * P,0.05,
** P,0.01 by two-tailed Mann-Whitney U test.
doi:10.1371/journal.pntd.0001406.g005
Figure 6. Changes in IgG1 to IgG2a ratios in the course of L. donovani infection. The ratios of antigen-specific IgG1 and IgG2a serum titres
(as shown in Fig. 5) were calculated for sera of each individual mouse within their respective vaccination group for both time points (day 28 and day
68). Error bars show standard error of the mean (SEM).
doi:10.1371/journal.pntd.0001406.g006
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nant Salmonella two reduced and one exacerbated disease
progression in a murine L. major infection model. These results
suggest that the frequency of identifying immunologically relevant
proteins by this method is high and may well be superior to
previous strategies that relied on mRNA expression and genome
data for antigen selection [51,52] with a hit frequency of ,15%.
Leishmania like other kinetoplastids regulate gene expression
mostly post-transcriptionally and mRNA abundance data alone
may not be informative to predict protein abundance. However, as
in shown in other systems [40] and Leishmania [53] actual protein
abundance in amastigotes is highly relevant if the protein is to
become a target of the immune response [54]. Analysis of the
proteome data sets suggested that bias in codon usage indicates
translational bias and therefore is highly correlated with protein
abundance [24]. Hence, codon usage may be used to rank ORFs
and serve as a substitute parameter for protein abundance in the
absence of real protein expression data to refine pure in silico
selection of candidate antigens. This becomes particularly relevant
for selecting membrane proteins that are severely underrepresent-
ed in current proteomic data sets.
The two protective antigens, LinJ08.1190 and LinJ23.0410,
expressed by Salmonella carriers were immunogenic in these
vaccines yet, based on antibody responses, were not a target of
the immune response to L. donovani infection, at least not in mice.
This is noteworthy since many Leishmania vaccine antigens
including KMP-11 currently favoured by other groups have been
identified using sera from patients [55–58]. Our findings with the
salmonella vectored KMP-11 vaccine suggest that these immuno-
selection approaches may introduce an extra hurdle for vaccine
development since the natural antigen-specific response may be
skewed and, possibly, even be disease exacerbating [59,60]. The
requirement for an additional type 1 immune response inducing
adjuvants, IL-12, to achieve protective effects with a KMP-11
DNA vaccine in the murine L. major model [61] is in good
agreement with this idea. Furthermore, a fusion protein called
LEISH-F1 - also known as Leish-110F, Leish-111f or MML – was
derived from the sequence of three immunoselected parasite
antigens. LEISH-F1 is the most advanced protein-based subunit
Leishmania vaccine in trial to date and has shown promising
effects when tested in a therapeutic setting against human
American CL [62]. However, this is not the case when used to
prevent visceral canine disease after high dose experimental
infection [63] or to treat naturally acquired VL in dogs [64]. In
contrast, LeishmuneH, a vaccine based on a glycoproteic fraction
of L. donovani that was not immunoselected, is licensed for the
prevention of canine VL in Brazil and has shown efficacy in the
field [65]. Interestingly, the LeishmuneH vaccine antigens are
poorly recognized by sera from dogs suffering from VL and
vaccination therefore is not interfering with sero-surveillance
programs [65]. Thus, reverse vaccinology based approaches as
Figure 7. Hepatic granulomatous response in vaccinated mice.
Liver sections were taken from mice used to assess parasite burden
(Fig. 4) and stained for iNOS and F4/80. Nuclei were counterstained with
DAPI. (A). Number of granulomas per 50 random fields of view (n=5
mice per time point). (B and C) Granuloma maturation status was
graded as described in Materials and Methods into no response
(hatched bar), immature (open bar), mature (grey bar) and empty (black
bar). Data were obtained from ,50 granulomas per mouse and 4–5
mice at both day 28 (B) and day 68 (C) post infection. D. iNOS staining
was assessed by determining the proportion of granuloma macrophage
area that was stained for iNOS. Data are derived from between 35–90
granulomas from 5 mice per time point.
doi:10.1371/journal.pntd.0001406.g007
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protective antigens.
A number of subunit vaccine delivery platforms, including
purified proteins or mixtures of glycans and glycoproteins,
recombinant DNA, viral and bacterial vectors have been evaluated
experimentally in murine models of leishmaniases (review by [12].
However, very few have entered or passed clinical testing and
amongst them no vectored vaccine. We have chosen Salmonella as a
carrier since these bacteria had already been positively evaluated by
several groups in experimental models of leishmaniases [25–27].
Moreover, they arebeing developedasrecombinant carriers against
a number of pathogens including Helicobacter pylori, Hepatitis B virus
and Plasmodium falciparum [66,67]. In the context of a major
neglected disease such as VL, their main advantages are their
excellent safety profile, simple and low-cost production at industrial
scale, possibility to store as lyophilized product at room tempera-
ture, and oral application route, thus reducing the requirements for
extensive infrastructure. In addition, Salmonella are potent inducers
of long-lived cell-mediated immunity including CD8
+ T cells
[28,68]. Induction of CD8
+ T cells is particularly efficient by
vaccines delivered by viral or bacterial carriers and may be a crucial
characteristic of anti-Leishmania vaccines, since both CD4
+ and
CD8
+ T cells are required for optimal anti-leishmanial immunity
andgranulomaformation[15–18].Whilewedonot yethaveformal
proof that our vaccines induced antigen-specific CD8
+ T cells,
bioinformatics analysis using CD8 T cell epitope/HLA-binding
peptide prediction algorithms suggested epitopes presentable by
major HLA alleles e.g. of human populations in VL endemic areas
in India [69]. In the context of VL, Salmonella have the additional
property to generate viscerotropic immune responses which may
explain that the main protective effect was observed at the level of
visceralizing infection in the L. major model. Moreover, depending
on serovar, S. enterica exhibits broad or narrow host ranges. Serovar
Typhimurium that was used here has the potential to deliver
vaccine antigens in humans [70] as well as in dogs [71–73] while
attenuated S. enterica Typhi can be engineered to deliver human
vaccines [30,66].
In summary, we report the identification of two novel candidate
vaccine antigens against VL by reverse vaccinology and the
optimized construction of live Salmonella carriers. These VL
vaccines could potentially be used to combat VL in the zoonotic,
as well as the anthroponotic cycle of the disease.
Supporting Information
Figure S1 Post-column fractions of purified his-tagged
antigens. His-tagged Leishmania antigens were expressed and
purified from E. coli cell from inclusion bodies (LinJ23.0410 (A);
LinJ08.1190 (B)) or lysates (KMP11 (C)) using nickel column liquid
chromatography as described in Materials and Methods. Collected
fractions were separated on SDS-Gels to determine yield and
purity and selected fractions (box) were pooled and subsequently
subjected to downstream processing such as dialysis and
ultrafiltration.
(TIF)
Figure S2 Two-step strategy for the selection of vaccine
strains expressing cytosolic KMP-11 for in vivo testing.
Bacterial fitness (top panel) was determined as ability of the
vaccine strain to colonize the Peyer’s patches of mice seven days
after single dose oral administration of 10
10 CFU with KMP-11
expressing SL3261 (open symbols) or carrier SL3261 control
(closed symbol; Schroeder and Aebischer (32)). For antigen
expression (bottom panel), bacterial strains were grown under
conditions mimicking the intraphagosomal environment (low
Mg
2+,C a
2+) and thus activating PpagC promoter activated vaccine
antigen expression. Translational efficiency depended on ribo-
somal binding site sequences that were the only difference between
expression plasmids pcVAC0-3. 20 mg whole bacterial lysate per
strain was loaded onto SDS gels and bands were visualized by
coomassie stain. Black arrowhead indicates induced protein of
interest (KMP-11).
(TIF)
Figure S3 Pilot-study to identify vaccine strains protec-
tive against L. major infection. Mice (10 per group) were
immunised orally with a single dose of 10
10 CFU of Salmonella
vaccine strains carrying the indicated vaccine antigen expression
plasmids or the carrier control SL3261. Twelve weeks later
animals were challenged with 2610
6 L. major promastigotes into
the left hind foot pad. Lesion size (A) was monitored with a calliper
using the uninfected right foot as reference. Values represent mean
swelling in mm and bars show standard errors of the mean (SEM).
Asterisks denote statistical thresholds * P#0.05, ** P#0.01,
*** P#0.001 determined by two-tailed Mann-Whitney U test. Seven
weeks after infection, three mice per group were randomly selected
for determination of parasite burden in the foot pad (B), draining
lymph node (D and spleen (C) were by limiting dilution assay as
described in Materials and Methods. n.d. denotes not determined.
(TIF)
Table S1 Organ and body weights were determined for
each mouse in the respective groups immunized with
SL3261 or SL3261 carrying the indicated vaccine antigen
expression plasmid in comparison to a group of
untreated mice. Five mice per group per time point were
killed by cervical dislocation and livers and spleens were removed
and weighed. The body-mass indices (BMIs; see Fig. 4 in main
manuscript) were calculated based on the mean weight values.
n.d.=not done.
(XLS)
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